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Abstract
Bipolar rapid cycling (RC) is defined as 4 or more affec-
tive episodes within 1 year. It has been postulated that
RC is related to a poor response to lithium, to the same
extent as mixed episodes or other atypical symptoms of
the illness. This article reviews the current status of alter-
native pharmacological or otherwise supportive thera-
pies of RC. Biological parameters and characteristics of
the illness associated with RC like gender prevalence in
women, hyperthyroidism, catecholamine-O-methyl-
transferase allele, the influence of sleep, different sub-
types of bipolar disorder and the risk of antidepressant-
induced cycling will be discussed in detail.
Copyright © 2002 S. Karger AG, Basel
Introduction
Rapid cycling (RC) as a longitudinal subtype of bipolar
disorder is characterized by the presence of 4 or more
depressed, hypomanic, mixed or manic episodes within 1
year. Episodes may occur in an arbitrary sequence with or
without a free interval.
The term ‘rapid cycling’ was introduced by Dunner
and Fieve [1] in 1974. It was deduced from the results of a
prophylaxis study with lithium showing inferior response
in those patients who had had at least 4 affective episodes
during the preceding year [1]. However, it took 20 years
until this definition was adapted by the Diagnostic and
Statistical Manual of Mental Disorders IV (DSM IV) [2],
and RC has not yet become a valid term in the Interna-
tional Classification of Diseases 10 (ICD 10). Clinical
reality, however, is the fact that at least 1/5 of bipolar
patients experience an RC course at some stage of their
illness. RC may be present right from the start of the ill-
ness or may develop during its course, often induced by
antidepressant treatment [3, 4].
Special subtypes of RC include ultra-RC (URC) with a
change of affective deflections within days or weeks and
ultra-ultra-RC (or ultradian RC) with continuous mood
instability. It has been suggested that mixed episodes are
just cycling with highest frequency or ‘ultramaximal cy-
cling’.
Characteristics and Risk Factors for RC
Prevalence and Gender
It has been estimated that 13–20% of bipolar patients
suffer from RC [4] with a much higher incidence when
looking into patients in special settings [5]. For example,
23 out of 54 patients who had been included in our Stan-
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ley Foundation bipolar outpatient clinics in 1999–2000
exhibit RC (42%); 52% of these rapid cyclers are female.
This differs slightly from the literature where 70–90% of
rapid cyclers are female. Consequently, the female gender
has been discussed as a risk factor for RC [5–8]. Searching
for an underlying biological factor, at least the theory that
RC is bound to the menstrual cycle could not be verified
[9].
Circadian Rhythm
Disturbances of the sleep-wake cycle are a general fea-
ture in bipolar patients. Feldman-Naim et al. [10] demon-
strated in 15 RC patients that a switch from depression
into mania or hypomania is more likely to occur during
the daytime, whereas the opposite happens preferentially
at night. It can be concluded from these data that
extended sleep periods may be helpful in manic RC
patients whereas increased activity and light therapy are
helpful tools in treating depressed rapid cyclers. This is
supported by another study [11] where the best predictor
for the development of hypomania or mania in 11 RC
patients followed over 18 months was the reduced sleep in
the night prior to a switch. Consequently, social rhythm
therapy as a psychotherapeutic treatment approach fo-
cuses on a stable sleep-wake cycle in RC patients [12].
Thyroid
Hypothyroidism has frequently been associated with
RC [13–15]. A first report from Cowdry et al. [15] in 1983
demonstrated a hypothyroid metabolism in 12 out of 24
RC patients, in contrast to 19 non-RC patients with no
abnormality. An increased concentration of thyroid anti-
bodies has been observed by Kupka et al. [16] in bipolar
patients. This finding was true in all bipolar patients and
not specially related to RC [16]. However, there are also
contradictory reports [7, 17]. Nevertheless, addition of
thyroid hormones appears to be successful in selected RC
patients [18–20]. This is also supported by a study of Sack
et al. [21] demonstrating a dysfunctional hypothalamus-
pituitary-thyroid axis. The healthy controls showed a sig-
nificant circadian variation of the thyroid-stimulating
hormone release which could be increased by sleep depri-
vation. This reactivity of thyroid-stimulating hormone
was not observed in patients with RC.
Regarding the aetiology, lithium-induced hypothyroid-
ism cannot be ruled out completely. A retrospective study
in 718 patients receiving lithium for at least 15 months
demonstrated a prevalence of 10.4% for hypothyroidism
[22]. Female patients had a higher risk than male (14 vs.
4.5%), especially during the first 2 years of treatment.
Catecholamines
Recently, a defect of the catecholamine-O-methyl-
transferase (COMT) has been discussed as an underlying
pathophysiology [23–27]. COMT metabolizes dopamine,
norepinephrine and epinephrine. A relation between bi-
polar disorder and catecholamine metabolism has been
suggested and may be deduced both from symptoms as
increased or decreased energy, and the usefulness of anti-
depressants for bipolar depression or dopamine antago-
nists in treating mania. A recent case report on a 48-hour
URC patient demonstrated increased concentrations of
metanephrine and epinephrine in the urine during manic
episodes [28].
Thus, increased or decreased activity of COMT may
relate to bipolar symptoms through an increase or de-
crease in catecholamines. Whereas there is no clear evi-
dence for such a disturbance in bipolar patients in general
[23, 25], an association with the low-activity allele of
COMT has been observed in RC and URC patients [24,
26].
Antidepressants
A hot topic of scientific discussion is the use of antide-
pressants in bipolar depression. Antidepressants may in-
duce mania or increase the frequency of RC [7, 29–32].
Tondo et al. [30] reported on 67 patients with bipolar dis-
order, with 40 patients developing an RC course after
long-term treatment with antidepressants. This appears
especially true for tricyclic antidepressants. Selective sero-
tonin reuptake inhibitors appear to have at least a lower
switch risk [33]. Other substances with a low switch risk
are lamotrigine (LTG) and the monoamine oxidase inhib-
itor moclobemide [34].
However, it is probably a premature conclusion to pro-
mote the monotherapy with a mood stabilizer and to
abstain from the use of antidepressants in bipolar depres-
sion [35]. Equal efficacy of a mood stabilizer compared to
an antidepressant in treating depression has not yet been
shown convincingly. Aspects as chronification of depres-
sion and suicidality need to be considered. Thus, the com-
bination treatment with an antidepressant and a mood
stabilizer should be the first-choice treatment [36–38].
This may be effective both in treating depressive symp-
toms and reducing the suicide and switch risk. However,
antidepressants should probably be discontinued earlier
in RC patients compared to non-RC patients.
Bipolar II Disorder
It has been suggested that RC is more common in bipo-
lar II than in bipolar I disorder [17, 39]. This is backed up
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by data from patients of our Stanley Foundation Bipolar
Network outpatient clinics. As of the end of 2000, 30% of
our patients with bipolar I and 73% with bipolar II disor-
der suffered from RC.
Psychopharmacological Treatment Strategies
The history of RC patients is often characterized by a
variety of unsuccessful treatment attempts. So far, an
unequivocal standard treatment is still missing. The state
of the art of pharmacological and other supportive treat-
ment options will be illustrated in the following para-
graphs.
Lithium
Lithium is still considered as a first-choice therapy for
the acute and maintenance treatments of classical bipolar
I disorder [36, 40, 41]. With the occurrence of dysphoric
mania, mixed states and especially RC, the response rate
of lithium sharply drops [42–47]. Historically, the term
‘rapid cycling’ was created when Dunner and Fieve [1]
analysed clinical factors associated with lithium non-
response in maintenance treatment. In this study, 82% of
RC patients were lithium non-responders compared to
41% of non-RC patients. Kukopulos et al. [29] surveyed
434 patients both with a classical course of bipolar disor-
der and with RC. 20% had an RC course with more
female than male patients affected. Out of the 87 patients
with RC, 16 had bipolar I and 71 bipolar II disorder. In
this study, lithium appeared also ineffective in RC.
A study of Baldessarini et al. [39] involved 360 patients
with bipolar I and II disorder with a follow-up of an aver-
age of 13.3 years; 56 (15.6%) had a history of RC with 41
(71%) fulfilling RC criteria during the previous year. Only
29.4% of all patients had no recurrence during the obser-
vation period. 31.7% of non-RC patients compared to
only 13.7% of RC patients were lithium responders.
Valproate
During the 1980s, some case reports suggested a bene-
ficial effect of valproate (VPA) in RC patients [48–50]. An
open prospective study of Calabrese et al. [51] in 78
patients followed up for an average of 15.8 months sup-
ports both an acute and prophylactic efficacy of VPA in
RC patients. Whereas the acute antidepressive efficacy of
VPA was low, 54% of manic and 94% of mixed patients
responded to VPA. Additionally, VPA was effective in
preventing new episodes, interestingly also in preventing
new depressive episodes in RC patients [51]. The most
common side-effect was gastro-intestinal upset. Using
special slow-release formulations may be helpful in pre-
venting these side-effects [52].
Subsequent but smaller open monotherapy trials with
VPA [53, 54] as well as studies combining VPA with lithi-
um or carbamazepine (CBZ) [55–57] support the impres-
sion of the usefulness of VPA in RC. Additionally, VPA
may be helpful in URC [28, 58]. However, large confir-
mative studies are still missing.
Carbamazepine
CBZ appears to be effective in treating acute mania
and preventing new episodes of bipolar disorder [59, 60].
Concerning the treatment of RC with CBZ, there is an
obvious lack of controlled data. Retrospective analyses of
small studies [61, 62] suggested efficacy of CBZ in RC
patients. However, the largest retrospective study analys-
ing 215 patients over 2 years gave no evidence of efficacy
in RC patients both for CBZ and lithium [63]. This view
is supported by a recent double-blind study comparing
lithium and CBZ. For 1 year, patients received either lith-
ium or CBZ. Non-responders were re-randomized to the
respective drug for another year. Those patients showing
no improvement after the second year were then treated
with lithium and CBZ for the third year. As a result, 28%
of the RC patients responded to lithium, but only 19%
had a benefit from CBZ [64].
In conclusion, the studies so far do not support the use
of CBZ in RC patients. Furthermore, most RC patients
receive combination treatments with several mood-stabi-
lizing drugs. As CBZ induces P450 enzymes and thus
increases drug metabolism, the efficacy of co-medication
may be reduced [65].
Lamotrigine
LTG has recently become a focus of interest in the
treatment of bipolar disorder, especially bipolar depres-
sion. Calabrese et al. [66] proved antidepressive efficacy
both for LTG 50 mg/day as well as 200 mg/day compared
to placebo.
Several case reports on LTG gave hints for efficacy in
RC. This is true both for monotherapy with LTG as well
as combination treatment [67–75]. Finally, Calabrese et
al. [76] supplied evidence for the efficacy of LTG in a
large double-blind prospective study: 324 RC patients ini-
tially received LTG as an add-on medication; 182 pa-
tients were stabilized and randomized to either placebo or
LTG maintenance treatment after discontinuation of oth-
er psychotropic medication. After 6 months, no signifi-
cant difference was observed between groups with respect
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to the primary outcome parameter ‘time to intervention’.
However, for the secondary outcome parameter ‘time in
study’ a significant difference was observed in favour of
LTG. Patients receiving LTG remained for an average of
6 weeks longer in the study; 41% of the LTG group com-
pared to 26% of the placebo group had no new episode.
Comparing RC patients with bipolar I and bipolar II dis-
order, the latter had more profit. No serious side-effects,
especially allergic reactions, were observed.
Thyroid Hormone Augmentation
Already in 1982, the first report came out demonstrat-
ing the usefulness of supraphysiological doses of L-thyrox-
ine in 5 out of 10 so far refractory RC patients [77].
Besides several case reports, a few open studies on bipolar
patients with or without RC back up these findings [19,
20]. In the study of Bauer and Whybrow [19], 11 pre-
viously refractory RC patients experienced with thyrox-
ine a reduction of episodes as well as a reduction of the
amplitude of mood swings. Four patients had a complete
remission. The same group was followed up for an average
duration of 2.5 years, and refractory bipolar patients
received L-thyroxine as an adition to mood stabilizers
[20]. In 20 patients, the number of episodes significantly
declined; 8 patients had no further episode.
Doses of L-thyroxine in these studies ranged from 200
to 500 Ìg/day, in some cases up to 600 Ìg/day. The most
frequent side-effects were sweating, an increase in tremor,
an increased heart rate and transient ankle oedema. No
severe cardiac side-effects or marked osteoporosis caused
by L-thyroxine have been observed in the studies so far
[78].
Calcium Antagonists
The hypothesis of a disturbed calcium homoeostasis
[79] in affective disorders led to testing calcium antago-
nists in RC patients. In an open design, 12 RC patients
received either lithium or nimodipine or the combination
of both [80]. The combination treatment was superior to
both monotherapies suggesting a synergistic effect of lithi-
um and nimodipine [81].
Twelve URC patients received nimodipine in a place-
bo-controlled double-blind study. Five out of 9 patients
finishing the study responded to nimodipine [82]. In
another study, the same group demonstrated efficacy of
nimodipine monotherapy in 10 out of 30 patients refrac-
tory so far to other mood stabilizers. In a second step, the
addition of CBZ to nimodipine was helpful in 4 out of 14
non-responders [83]. Nimodipine is a generally well-toler-
ated drug; however, due to its short half-life, it has to be
taken 3–4 times a day which may definitely cause com-
pliance problems.
Atypical Antipsychotics
Atypical antipsychotics are increasingly used in the
treatment of bipolar disorder [84]. Clozapine was the first
atypical antipsychotic tested in affective disorders [85]. It
has a unique receptor profile combining 5-HT2- and
dopamine D1–D5 antagonism. Although mainly used in
refractory patients, clozapine appears useful in treating
both mania and RC [86–90].
As far as the new generation of atypical antipsychotics
is concerned, there is first evidence for a positive effect of
risperidone in RC patients. In a 6-month mirror image
comparison of 10 RC patients, Vieta et al. [91] showed
benefit of risperidone in 8 of 10 RC patients. However,
not only for clozapine and risperidone, but for all atypical
antipsychotics, large-scale controlled trials are still miss-
ing to establish undoubtful efficacy in the treatment of
RC.
Psychotherapy
Psychotherapy in bipolar patients in general still needs
more scientific evaluation. Especially in RC patients, no
controlled data are available. There is one case report
showing the advantage of combined cognitive behaviour-
al therapy and pharmacological treatment compared to
drug monotherapy [92].
Further Treatment Options
Electroconvulsive Therapy
Electroconvulsive therapy is still the most effective
treatment of affective disorders, both for depressive [93]
and manic episodes [94, 95]. For RC patients, a case
report [96] and an open case series of 20 patients with
treatment-refractory affective and schizo-affective disor-
ders [97] gave at least a hint to effectiveness of electrocon-
vulsive therapy in RC.
Magnesium
In a small open case series of 9 refractory RC patients,
4 patients receiving 40 mEq/day magnesium aspartate
hydrochloride improved [98]. The rationale behind the
study was the chemical similarity between magnesium
and lithium. However, subsequent studies following up
these findings are still missing.
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Choline
Six RC patients were treated with choline in an open
design [99]. Choline was well tolerated, and 4 patients
showed marked improvement of their affective symp-
toms. Again, large-scale controlled trials are still missing
to back up the efficacy of choline in RC.
Conclusion
RC is a difficult-to-treat condition and may have a dis-
astrous impact on patients. The quality of life is severely
impaired due to the frequent episodes and subsequent
hospitalizations. In contrast to the severity of this condi-
tion, there is a paucity of knowledge on treatment which is
backed up by scientific studies. Thus, we still have to rely
mainly on open case series and small uncontrolled stud-
ies.
Manic Episode within RC
Evidence so far suggests that lithium is less effective in
RC than in non-RC bipolar patients. Large case series
show that VPA may be more effective. Alternatively, CBZ
or atypical antipsychotics should be tried if VPA fails.
Additionally, social rhythm therapy leading to sufficient
sleep and the avoidance of too much light exposure may
be helpful.
Depressive Episodes within RC
Tricyclic antidepressants should be avoided as they
may induce mania and increase episode frequency. Se-
lective serotonin reuptake inhibitors are not only better
tolerated, but also have a lower risk of inducing a switch.
In every case, a mood stabilizer is mandatory as the basic
treatment. If depressive episodes are more frequent and
severer than manic ones, e.g. in bipolar II disorder, LTG
may become a future first-choice treatment. Additionally,
addition of supraphysiological doses of L-thyroxine
should be tried in refractory patients.
Prophylaxis of RC
RC is associated with an inferior response to lithium
maintenance treatment. Again, open data suggest a bene-
ficial effect of VPA. The data for CBZ are controversial;
some studies suggest superiority compared to lithium,
whereas others could not demonstrate any benefit of both
treatments. Again, LTG may become a future first-choice
treatment especially in bipolar II RC patients, and high
dose L-thyroxine or nimodipine may additionally stabi-
lize cycling patients.
Although the tendency is clearly towards combination
treatment in RC patients, regular checks for candidate
drugs to taper off should be performed. As suggested by
Wehr and Goodwin [100] and Kukopulos et al. [3], dis-
continuing antidepressants may already reduce the fre-
quency of episodes.
For the coming years, it can be expected that several
new candidates for the treatment of RC will appear on the
stage. This includes new atypical antipsychotics, e.g. que-
tiapine and ziprasidone, as well as new anticonvulsants,
e.g. topiramate or retigabine, and innovative treatments
like ˆ -3 fatty acids. Hopefully, more effort will be made to
obtain scientific proof for their efficacy in controlled stud-
ies in order to come to an evidence-based and optimized
treatment of RC.
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